Replies to post #221539 on Biotech Values

[vlad33301]

By and large, ESMO—>disaster for presenting companies.

Specifically, how did ADAP not know that it is going to get massacred on such data?

[DewDiligence]

DVAX—(+11%)—was one of the few exceptions:

https://finance.yahoo.com/news/dynavax-sd-101-combination-keytruda-124500879.html